27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Amyloid-beta peptide (Abeta) seems to have a central role in the neuropathology of Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The distribution and density of neurofibrillary tangles and amyloid plaques was studied in a unique series of cases whose premortem cognitive status had been assessed with the Clinical Dementia Rating (CDR), including 39 nondemented cases (CDR = 0; age, 51-88 years), 15 very mildly demented cases (CDR = 0.5), and 8 severely demented (CDR = 3) cases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
At the end of the study cognitive function had deteriorated among those in the placebo group. 4 key findings →
Participants: 725 Evidence: high
Full summary, score breakdown and related studies → Original source
C oronary heart disease (CHD) is the single leading cause of death and a significant cause of morbidity among American women. 1 Risk factors for CHD in women are well documented. 2 Compelling data from epidemiological studies and randomized clinical trials show that CHD is largely preventable.
Participants: 2,763 Evidence: high
Full summary, score breakdown and related studies → Original source
The combined measure of CSF Abeta42 and tau meets the requirements for clinical use in discriminating AD from normal aging and specific neurologic disorders. 4 key findings →
Participants: 84 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Structural maturation of fiber tracts in the human brain, including an increase in the diameter and myelination of axons, may play a role in cognitive development during childhood and adolescence. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The epsilon2 allele confers a protective effect, and women with DS have an increased risk for AD, as in the general population. 5 key findings →
Participants: 57 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The relationship between NFD and Alzheimer-type dementia, and the criteria for a biochemical diagnosis of AD, are documented, and an association between AD and the extent of NFD in defined brain areas is shown. 1 key finding →
Participants: 60 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Clinical management of DLB patients usually centers on the treatment of noncognitive features. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Although the Mini-Mental State Examination (MMSE) is widely used in clinical practice, few norms exist for healthy populations covering a broad range of ages. 4 key findings →
Participants: 908 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our study suggests that being a caregiver who is experiencing mental or emotional strain is an independent risk factor for mortality among elderly spousal caregivers.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study describes automated procedures for obtaining accurate and explicit reconstructions of the human cortical surface. 3 key findings →
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Genetic evidence strongly supports the view that Abeta amyloid production is central to the cause of Alzheimer's disease.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There were no group differences with any of the outcome measures in an intent-to-treat analysis. 5 key findings →
Participants: 41 Evidence: high
Full summary, score breakdown and related studies → Original source
Citicoline has been extensively used for the treatment of neurodegenerative disorders associated with head trauma, stroke, brain aging, cerebrovascular pathology and Alzheimer's disease. 5 key findings →
Participants: 17 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There was no relation between the amount of NIH funding and the incidence, prevalence, or number of hospital days attributed to each condition or disease (P=0.82, P=0.23, and P=0.21, respectively). 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A proportional increase in ADC compared with other ADIs and a marked increase in the median CD4 cell count at ADC diagnosis have occurred since the introduction of HAART in Australia. 5 key findings →
Participants: 1,049 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Analyzing data from more than 1,500 family caregivers from the 1996 National Caregiver Survey, this study documents the ways in which dementia care is different from other types of family caregiving. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study demonstrates that, even in apparently healthy subjects, age-associated immune activation indicated by raised levels of pro-inflammatory cytokines may reflect age-associated pathological processes that develop over decades. 1 key finding →
Participants: 45 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cross sectional analysis comparing prospectively collected research data with MDS data reported from nursing homes on identical subjects. 4 key findings →
Design: longitudinal study Participants: 140 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We assessed the risk of dementia by educational level in a prospective population-based study. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The results of the cost-effectiveness model presented here suggest that donepezil may be cost-effective but additional controlled data on long-term drug efficacy are needed. 5 key findings →
Design: cross-sectional Evidence: high
Full summary, score breakdown and related studies → Original source
Selegiline has a long-term beneficial effect in Alzheimer's disease on memory modalities that reflect the function of the prefrontal areas of the brain, which are rich in dopamine receptors. 5 key findings →
Participants: 143 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Owing to the pharmacokinetic properties of physostigmine when administered by conventional routes, long-term cholinergic treatment of Alzheimer's disease is difficult to manage. 3 key findings →
Participants: 204 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In common with Alzheimer's disease and vascular dementia, PVHs and WMHs were significantly more extensive in dementia with Lewy bodies than in controls. 5 key findings →
Participants: 27 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →